Jonathan Young Akero Therapeutics, Inc. (AKRO) insider trading activity

Jonathan Young is Chief Operating Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 0 shares of AKRO, which is worth approximately $0. The most recent transaction as insider was on Dec 09, 2025, when has been sold 200,189 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Jonathan Young Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 09 2025	SELL Sale (or disposition) back to the issuer	-	200,189 Reduced 100.0%	0 Common Stock
Nov 26 2025	SELL Bona fide gift	-	9,259 Reduced 4.42%	200,189 Common Stock
Nov 24 2025	BUY Exercise of conversion of derivative security	$295,050 $23.51 p/Share	12,550 Added 5.65%	209,448 Common Stock
Oct 01 2025	SELL Open market or private sale	$597,625 $47.81 p/Share	12,500 Reduced 5.97%	196,898 Common Stock
Oct 01 2025	BUY Exercise of conversion of derivative security	$263,750 $21.1 p/Share	12,500 Added 5.63%	209,398 Common Stock
Sep 11 2025	SELL Open market or private sale	$25,209 $43.02 p/Share	586 Reduced 0.3%	196,898 Common Stock
Sep 02 2025	SELL Open market or private sale	$585,375 $46.83 p/Share	12,500 Reduced 5.95%	197,484 Common Stock

Sep 02 2025	BUY Exercise of conversion of derivative security	$263,750 $21.1 p/Share	12,500 Added 5.62%	209,984 Common Stock
Aug 12 2025	SELL Open market or private sale	$600,250 $48.02 p/Share	12,500 Reduced 5.95%	197,484 Common Stock
Aug 12 2025	BUY Exercise of conversion of derivative security	$263,750 $21.1 p/Share	12,500 Added 5.62%	209,984 Common Stock
Jun 30 2025	BUY Grant, award, or other acquisition	$21,244 $23.87 p/Share	890 Added 0.45%	197,484 Common Stock
Jun 18 2025	SELL Open market or private sale	$79,682 $54.84 p/Share	1,453 Reduced 0.73%	196,594 Common Stock
Jun 10 2025	SELL Open market or private sale	$134,597 $53.99 p/Share	2,493 Reduced 1.24%	198,047 Common Stock
Mar 12 2025	SELL Open market or private sale	$27,242 $44.88 p/Share	607 Reduced 0.3%	200,540 Common Stock
Mar 04 2025	SELL Open market or private sale	$2,231,000 $44.62 p/Share	50,000 Reduced 19.91%	201,147 Common Stock
Feb 03 2025	SELL Open market or private sale	$538,100 $53.81 p/Share	10,000 Reduced 3.83%	251,147 Common Stock
Jan 24 2025	BUY Exercise of conversion of derivative security	$273,887 $6.36 p/Share	43,064 Added 14.16%	261,147 Common Stock
Jan 02 2025	SELL Open market or private sale	$280,300 $28.03 p/Share	10,000 Reduced 4.38%	218,083 Common Stock
Dec 16 2024	BUY Grant, award, or other acquisition	-	24,300 Added 9.63%	228,083 Common Stock
Dec 10 2024	SELL Open market or private sale	$77,067 $30.79 p/Share	2,503 Reduced 1.21%	203,783 Common Stock
Dec 02 2024	SELL Open market or private sale	$321,300 $32.13 p/Share	10,000 Reduced 4.62%	206,286 Common Stock
Nov 01 2024	SELL Open market or private sale	$1,630,519 $32.15 p/Share	50,716 Reduced 18.99%	216,286 Common Stock
Nov 01 2024	BUY Exercise of conversion of derivative security	$858,700 $21.09 p/Share	40,716 Added 13.23%	267,002 Common Stock
Oct 14 2024	SELL Open market or private sale	$1,206,000 $30.15 p/Share	40,000 Reduced 15.02%	226,286 Common Stock
Oct 14 2024	BUY Exercise of conversion of derivative security	$843,600 $21.09 p/Share	40,000 Added 13.06%	266,286 Common Stock

Jonathan Young

Chief Operating Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account